Jacobs Levy Equity Management, Inc Biocryst Pharmaceuticals Inc Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 367,514 shares of BCRX stock, worth $2.67 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
367,514
Previous 739,599
50.31%
Holding current value
$2.67 Million
Previous $4.57 Million
38.88%
% of portfolio
0.01%
Previous 0.02%
Shares
14 transactions
Others Institutions Holding BCRX
# of Institutions
280Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$148 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$145 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$86.3 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$66.1 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$64.3 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.35B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...